Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
MRNA Forecast Markets
Moderna, Inc.
6
Active Markets
1
Resolved
33%
Avg Probability
All Markets
7 markets
Will the CDC/ACIP reclassify COVID vaccination from universal to risk-based recommendation by December 31, 2027?
22%
Likely No
94% agreement
Jan 31, 2028
IG: 0.80
Will Moderna receive a clear regulatory path forward for mRNA-1010 (flu vaccine) from the FDA Type A meeting by September 30, 2026?
28%
Likely No
93% agreement
Oct 15, 2026
IG: 0.80
Will Moderna report positive Phase 3 results for intismeran (mRNA-4157) in adjuvant melanoma by December 31, 2026?
37%
Likely No
94% agreement
Jan 31, 2027
IG: 0.80
Will Moderna lose the Arbutus patent trial and be ordered to pay royalties of 5% or higher on LNP-based products?
25%
Likely No
92% agreement
Jun 30, 2026
IG: 0.64
Will the FDA issue a Refuse-to-File on any additional Moderna application (beyond mRNA-1010) by December 31, 2026?
16%
Likely No
94% agreement
Jan 31, 2027
IG: 0.60
Will Moderna receive regulatory approval for mRNA-1010 (flu vaccine) in the EU, Canada, or Australia by December 31, 2026?
74%
Likely Yes
94% agreement
Jan 31, 2027
IG: 0.48
Will Moderna report Q4 2025 year-end cash below $7.0B or issue 2026 revenue guidance below $1.5B?
32%
Likely No
Actual: NO
Brier: 0.102Feb 13, 2026
IG: 0.60
Resolution Timeline
Mar 15, 2026RESOLVED
Will Moderna report Q4 2025 year-end cash below $7.0B or issue 2026 revenue guidance below $1.5B? NOBrier: 0.10